FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016352512> ?p ?o ?g. }

• W2016352512 endingPage "633" @default.
• W2016352512 startingPage "621" @default.
• W2016352512 abstract "Hepatitis C virus (HCV) NS3/4A protease is an important and attractive target for anti-HCV drug development and discovery. Vaniprevir (phase III clinical trials) and MK-5172 (phase II clinical trials) are two potent antiviral compounds that target NS3/4A protease. However, the emergence of resistance to these two inhibitors reduced the effectiveness of vaniprevir and MK-5172 against viral replication. Among the drug resistance mutations, three single-site mutations at residues Arg155, Ala156, and Asp168 in NS3/4A protease are especially important due to their resistance to nearly all inhibitors in clinical development. A detailed understanding of drug resistance mechanism to vaniprevir and MK-5172 is therefore very crucial for the design of novel potent agents targeting viral variants. In this work, molecular dynamics (MD) simulation, binding free energy calculation, free energy decomposition, residue interaction network (RIN), and substrate envelope analysis were used to study the detailed drug resistance mechanism of the three mutants R155K, A156T, and D168A to vaniprevir and MK-5172. MD simulation was used to investigate the binding mode for these two inhibitors to wild-type and resistant mutants of HCV NS3/4A protease. Binding free energy calculation and free energy decomposition analysis reveal that drug resistance mutations reduced the interactions between the active site residues and substituent in the P2 to P4 linker of vaniprevir and MK-5172. Furthermore, RIN and substrate envelope analysis indicate that the studied mutations of the residues are located outside the substrate (4B5A) binding site and selectively decrease the affinity of inhibitors but not the activity of the enzyme and consequently help NS3/4A protease escape from the effect of the inhibitors without influencing the affinity of substrate binding. These findings can provide useful information for understanding the drug resistance mechanism against vaniprevir and MK-5172. The results can also provide some potential clues for further design of novel inhibitors that are less susceptible to drug resistance." @default.
• W2016352512 created "2016-06-24" @default.
• W2016352512 creator A5002139847 @default.
• W2016352512 creator A5027345342 @default.
• W2016352512 creator A5054987508 @default.
• W2016352512 creator A5090895839 @default.
• W2016352512 date "2013-06-28" @default.
• W2016352512 modified "2023-10-16" @default.
• W2016352512 title "Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network, and Substrate Envelope Analysis" @default.
• W2016352512 cites W1549357029 @default.
• W2016352512 cites W1964624100 @default.
• W2016352512 cites W1965894900 @default.
• W2016352512 cites W1966043736 @default.
• W2016352512 cites W1968642415 @default.
• W2016352512 cites W1975580333 @default.
• W2016352512 cites W1976161355 @default.
• W2016352512 cites W1976499671 @default.
• W2016352512 cites W1980075189 @default.
• W2016352512 cites W1982874561 @default.
• W2016352512 cites W1983144547 @default.
• W2016352512 cites W1983151339 @default.
• W2016352512 cites W1984247615 @default.
• W2016352512 cites W1984695931 @default.
• W2016352512 cites W1984897642 @default.
• W2016352512 cites W1988562891 @default.
• W2016352512 cites W1989831705 @default.
• W2016352512 cites W1995704702 @default.
• W2016352512 cites W2001390174 @default.
• W2016352512 cites W2004660555 @default.
• W2016352512 cites W2009708267 @default.
• W2016352512 cites W2014509089 @default.
• W2016352512 cites W2019574809 @default.
• W2016352512 cites W2023228519 @default.
• W2016352512 cites W2027545702 @default.
• W2016352512 cites W2029323175 @default.
• W2016352512 cites W2030045109 @default.
• W2016352512 cites W2038314839 @default.
• W2016352512 cites W2043120072 @default.
• W2016352512 cites W2043570667 @default.
• W2016352512 cites W2045640395 @default.
• W2016352512 cites W2048986518 @default.
• W2016352512 cites W2055337326 @default.
• W2016352512 cites W2056002345 @default.
• W2016352512 cites W2056944867 @default.
• W2016352512 cites W2057186508 @default.
• W2016352512 cites W2067174909 @default.
• W2016352512 cites W2069123478 @default.
• W2016352512 cites W2072655657 @default.
• W2016352512 cites W2075369230 @default.
• W2016352512 cites W2080696565 @default.
• W2016352512 cites W2083271125 @default.
• W2016352512 cites W2086246898 @default.
• W2016352512 cites W2091724766 @default.
• W2016352512 cites W2093381148 @default.
• W2016352512 cites W2097148041 @default.
• W2016352512 cites W2101414808 @default.
• W2016352512 cites W2103631613 @default.
• W2016352512 cites W2106140689 @default.
• W2016352512 cites W2108851656 @default.
• W2016352512 cites W2112876622 @default.
• W2016352512 cites W2113264508 @default.
• W2016352512 cites W2115339329 @default.
• W2016352512 cites W2122854841 @default.
• W2016352512 cites W2129620576 @default.
• W2016352512 cites W2134970730 @default.
• W2016352512 cites W2139624902 @default.
• W2016352512 cites W2140231399 @default.
• W2016352512 cites W2140374568 @default.
• W2016352512 cites W2141361007 @default.
• W2016352512 cites W2144656637 @default.
• W2016352512 cites W2147993766 @default.
• W2016352512 cites W2149026172 @default.
• W2016352512 cites W2149263899 @default.
• W2016352512 cites W2153953580 @default.
• W2016352512 cites W2156879354 @default.
• W2016352512 cites W2157961528 @default.
• W2016352512 cites W2158177781 @default.
• W2016352512 cites W2159414436 @default.
• W2016352512 cites W2159675211 @default.
• W2016352512 cites W2160114627 @default.
• W2016352512 cites W2160858894 @default.
• W2016352512 cites W2203497712 @default.
• W2016352512 cites W2325652290 @default.
• W2016352512 doi "https://doi.org/10.1021/ci400060j" @default.
• W2016352512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23745769" @default.
• W2016352512 hasPublicationYear "2013" @default.
• W2016352512 type Work @default.
• W2016352512 sameAs 2016352512 @default.
• W2016352512 citedByCount "55" @default.
• W2016352512 countsByYear W20163525122013 @default.
• W2016352512 countsByYear W20163525122014 @default.
• W2016352512 countsByYear W20163525122015 @default.
• W2016352512 countsByYear W20163525122016 @default.
• W2016352512 countsByYear W20163525122017 @default.
• W2016352512 countsByYear W20163525122018 @default.
• W2016352512 countsByYear W20163525122019 @default.
• W2016352512 countsByYear W20163525122020 @default.
• W2016352512 countsByYear W20163525122021 @default.

• next